Recombinant influenza A viruses as vaccine vectors.
Genetic Vectors
Humans
Influenza A virus
/ genetics
Malaria, Falciparum
/ prevention & control
Plasmodium falciparum
/ immunology
Respiratory Syncytial Virus Infections
/ prevention & control
Respiratory Syncytial Viruses
/ immunology
Reverse Genetics
Vaccines, Attenuated
/ immunology
Vaccines, Synthetic
/ immunology
West Nile Fever
/ prevention & control
West Nile virus
/ immunology
Influenza virus
immunity
recombinant
reverse genetics
vaccine
vector
Journal
Expert review of vaccines
ISSN: 1744-8395
Titre abrégé: Expert Rev Vaccines
Pays: England
ID NLM: 101155475
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
pubmed:
20
2
2019
medline:
26
5
2020
entrez:
20
2
2019
Statut:
ppublish
Résumé
Various viruses, including poxviruses, adenoviruses and vesicular stomatitis virus, have been considered as vaccine vectors for the delivery of antigens of interest in the development of vaccines against newly emerging pathogens. Here, we review results that have been obtained with influenza A viruses (IAV) as vaccine vectors. With the advent of reverse genetics technology, IAV-based recombinant vaccine candidates have been constructed that induce protective immunity to a variety of different pathogens of interest, including West Nile virus, Plasmodium falciparum and respiratory syncytial virus. The various cloning strategies to produce effective and attenuated, safe to use IAV-based viral vectors are discussed. It was concluded that IAV-based vector system has several advantages and holds promise for further development.
Identifiants
pubmed: 30777467
doi: 10.1080/14760584.2019.1582338
doi:
Substances chimiques
Vaccines, Attenuated
0
Vaccines, Synthetic
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM